United Therapeutics Corporation (UTHR) CEO Martine A. Rothblatt Sells 2,176 Shares
United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 2,176 shares of United Therapeutics Corporation stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $127.11, for a total transaction of $276,591.36. Following the sale, the chief executive officer now owns 3,245 shares in the company, valued at $412,471.95. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of United Therapeutics Corporation (NASDAQ UTHR) traded up 1.73% during trading on Friday, hitting $129.22. 65,353 shares of the company’s stock were exchanged. The stock has a market cap of $5.61 billion, a PE ratio of 14.99 and a beta of 1.51. United Therapeutics Corporation has a 1-year low of $110.90 and a 1-year high of $169.89. The stock’s 50-day moving average price is $130.70 and its 200-day moving average price is $135.52.
United Therapeutics Corporation (NASDAQ:UTHR) last announced its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.61 by $4.86. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The firm had revenue of $444.60 million for the quarter, compared to analyst estimates of $391.53 million. During the same quarter in the previous year, the company earned $4.42 earnings per share. The company’s quarterly revenue was up 7.8% on a year-over-year basis. On average, equities analysts expect that United Therapeutics Corporation will post $10.70 earnings per share for the current fiscal year.
United Therapeutics Corporation announced that its board has authorized a share repurchase plan on Thursday, April 27th that authorizes the company to repurchase $250.00 million in outstanding shares. This repurchase authorization authorizes the biotechnology company to repurchase up to 4.6% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its stock is undervalued.
WARNING: This piece of content was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/08/11/united-therapeutics-corporation-uthr-ceo-martine-a-rothblatt-sells-2176-shares.html.
Large investors have recently bought and sold shares of the stock. BlackRock Inc. increased its stake in United Therapeutics Corporation by 3.3% in the second quarter. BlackRock Inc. now owns 4,897,334 shares of the biotechnology company’s stock worth $635,330,000 after buying an additional 155,349 shares during the last quarter. FMR LLC increased its stake in United Therapeutics Corporation by 2.4% in the first quarter. FMR LLC now owns 4,138,779 shares of the biotechnology company’s stock worth $560,308,000 after buying an additional 98,529 shares during the last quarter. Vanguard Group Inc. increased its stake in United Therapeutics Corporation by 7.3% in the first quarter. Vanguard Group Inc. now owns 3,785,099 shares of the biotechnology company’s stock worth $512,427,000 after buying an additional 256,514 shares during the last quarter. State Street Corp increased its stake in United Therapeutics Corporation by 7.6% in the first quarter. State Street Corp now owns 1,997,327 shares of the biotechnology company’s stock worth $270,411,000 after buying an additional 140,949 shares during the last quarter. Finally, Palo Alto Investors LLC increased its stake in United Therapeutics Corporation by 0.8% in the first quarter. Palo Alto Investors LLC now owns 1,883,315 shares of the biotechnology company’s stock worth $254,963,000 after buying an additional 14,500 shares during the last quarter.
Several analysts have recently weighed in on the stock. UBS AG reiterated a “sell” rating and set a $106.00 target price on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. ValuEngine raised shares of United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 13th. BidaskClub downgraded shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Jefferies Group LLC reissued a “sell” rating and set a $105.00 price target on shares of United Therapeutics Corporation in a report on Friday, July 14th. Finally, Zacks Investment Research downgraded shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Six equities research analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the stock. United Therapeutics Corporation currently has an average rating of “Hold” and a consensus target price of $134.50.
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.